Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Events

25 May 2016 - 27 May 2016
06 Jun 2016 - 09 Jun 2016
22 Jun 2016 - 24 Jun 2016

Drug Discovery

New Multiple Myeloma Mouse Model Should Advance Drug Development Efforts

A recently developed multiple myeloma mouse model is expected to aid in understanding the pathology of the disease and serve as a platform for preclinical testing of potential therapeutic agents. More...
18 May 2016

Inhibition of Cholesterol Esterification Suppresses Growth of Pancreatic Cancer Cells

A team of cancer researchers has suggested that controlling cholesterol metabolism within tumor cells represents a novel approach towards treating the disease. More...
18 May 2016

Antibodies against Complement Factor H Selectively Destroy Tumor Cells

Cancer researchers have identified and produced a monoclonal antibody that destroys tumor cells by blocking the activity of the protective protein complement factor H (CFH). More...
17 May 2016

Stem Cells Induced by Low Molecular Weight Compounds Transform into Working Heart and Brain Cells

A team of cell biologists has demonstrated the feasibility of using cocktails of low molecular weight compounds to induce skin cells to revert to a stem cell-like state that allowed them to be reprogrammed into cardiac or neural cells. More...
12 May 2016

Nanoparticle Treatment Prevents Herpes Infection in Mouse Model

A novel type of nanoparticle was shown to effectively prevent infection by herpes simplex virus-2 (HSV-2), the virus that causes chronic genital herpes. More...
10 May 2016

Adenoid Cystic Carcinoma Stem Cells Depend on NOTCH1 and SOX10 Signaling

Cancer researchers have isolated a stem cell population from the cells making up an adenoid cystic carcinoma (ACC) tumor and showed that the signaling factors NOTCH1 and SOX10 were essential for the cancer stem cells to proliferate and resist radiation treatment. More...
05 May 2016

Experimental Small-Molecule Anticancer Drug Blocks RAS-binding Domains

The experimental small-molecule anticancer drug rigosertib was shown to block tumor growth by acting as an RAS-mimetic and interacting with the RAS binding domains of RAF kinases, resulting in their inability to bind to RAS, which inhibited the RAS-RAF-MEK pathway. More...
04 May 2016


The Drug Discovery channel in BioResearch informs about the biotechnology of drug discovery and design from traditional to translational pharma within the five-year horizon.
Copyright © 2000-2016 Globetech Media. All rights reserved.